Blood test could replace needle biopsies for breast cancer staging
NCT ID NCT07304934
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study is testing a new blood test called TuFEst that uses DNA fragments and deep learning to stage breast cancer and check if it has spread to lymph nodes. Researchers will enroll 269 breast cancer patients, including those having surgery and those receiving chemotherapy before surgery. The goal is to see if this non-invasive test can accurately predict tumor burden, potentially reducing the need for surgical biopsies.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
What this could lead to
If successful, this could lead to a simple blood test that helps doctors stage breast cancer more accurately, potentially reducing the need for invasive biopsies.
What could go wrong
This is an early-stage study with only 269 participants. The test may not be accurate enough for widespread use, and results may not apply to all breast cancer patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.